A recent study published in the New England Journal of Medicine has found that heterozygosity for the APOE3 Christchurch variant is associated with a 4-5 year delayed onset of symptoms in individuals with a familial autosomal dominant form of Alzheimer's disease caused by the PSEN1E280A mutation. The study observed a 4-5 year delay in the onset of Alzheimer's symptoms despite increased β-amyloid but less Tau accumulation. This genetic trait could potentially be used to develop new antibody drugs for high-risk groups.
A Potential #Parkinson’s Treatment Has Promising Results In Early Trials. https://t.co/vk4wdvMX6W
More evidence supporting reducing APOE expression as therapeutic mechanism to treat Alzheimer's disease. In 2019, we learned about a Columbian woman who stunned scientists by defying the death sentence she was born with (https://t.co/p0UgCAKxa3). Despite carrying the PSEN1… https://t.co/cWbwuBd6cM
Could superagers be the key to deciphering Alzheimer's? https://t.co/0ulkomWx9X
Scientists just discovered a new genetic clue for delaying #Alzheimers disease. It’s already inspiring drug discovery. Read more in my story for @endpts about how scientists are designing drugs that mimic the protective APOE3 Christchurch mutation. https://t.co/UThOmpZmfn
Parkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement Neurons https://t.co/oUOcakVUzp #news #biotech
Scientists are trying to learn how to resist Alzheimer's from rare resilient patients https://t.co/NAtXXGx7lS
Researchers say a rare genetic trait could delay the onset of Alzheimer's in high-risk group and be used to develop antibody drugs. https://t.co/fk2bqqhLFP
Since 2007, @DrGoodenowe has researched and developed a treatment now being trialed by hundreds of doctors across America on Alzheimer’s sufferers. And, two children with a rare disease are rapidly and profoundly displaying this treatment’s effects. https://t.co/OvF2BLyXe9
Having 1 copy of a rare APO allele (Christchurch) provides some protection, 4-5 year delay, from a familial autosomal dominant Alzheimer's disease https://t.co/kDcUADfLkk @NEJM @ytquiroz @DrJoeArboleda despite increased β-amyloid, but less Tau accumulation https://t.co/KXcZotHfae
In a kindred with PSEN1E280A, which causes autosomal dominant Alzheimer’s disease, heterozygosity for the APOE3 Christchurch variant was associated with delayed onset of symptoms. Read the full study results: https://t.co/8OLLlB7UNw https://t.co/aRrNM84RtA